Published within
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Although the FDA's complete response letter for Cimzia in rheumatoid arthritis will delay its US approval, Datamonitor believes UCB has the experience to handle the setback and the drug may still reach the market by the second half of 2009. Ultimately however, the delay will not be a major impediment as extensive uptake is not expected at launch due to poor differentiation in a mature drug class.
Published By Datamonitor
|
07 Jan 2009 |
|
Expert View
|
Raptiva's safety profile continues to face US and EU regulatory agency scrutiny, which Datamonitor believes will have significant ramifications for the drug's use in psoriasis and any future employment in transplantation. With fresh concern over the safety of Genentech's drug, alternative therapies are likely to impact upon Raptiva's commercial potential.
Published By Datamonitor
|
23 Feb 2009 |
|
CommentWire
|
Following positive results from two Phase II trials, Genentech/Roche's Avastin has obtained accelerated FDA approval for glioblastoma patients who have progressed after previous treatment. While the commercial potential in this indication is small, it creates an opportunity for Avastin to become an established treatment in this type of brain cancer.
Published By Datamonitor
|
06 May 2009 |
|
CommentWire
|
Seattle Genetics and Millennium: the Takeda Oncology Company have announced encouraging results from a Phase II trial of brentuximab vedotin in relapsed or refractory Hodgkin's lymphoma. Full results of the trial are yet to be published, but the candidate looks set to become the first immunotherapy approved for the disease.
Published By Datamonitor
|
29 Sep 2010 |
|
CommentWire
|
Celgene has posted an increase in its Q3 and year-to-date sales compared to 2009 figures, which has led the company to raise its own 2010 total revenue forecasts from $3.45 billion to $3.6 billion. The company is expected to grow further out to 2015, as its looks to expand its global market share and product portfolio.
Published By Datamonitor
|
02 Nov 2010 |
|
Expert View
|
The FDA has recommended that metastatic breast cancer be removed from Avastin's label after reviewing survival data from Phase III clinical trials. Roche/Genentech has requested a public hearing about the decision, as the removal of breast cancer from the label will impact the drug's US sales. Furthermore, the decision indicates a new level of expectation for Avastin in terms of clinical outcomes.
Published By Datamonitor
|
17 Dec 2010 |
|
Expert View
|
The FDA has approved Rituxan for first-line maintenance treatment of patients with advanced follicular lymphoma that responded to initial treatment with Rituxan plus chemotherapy. Sales are expected to increase across the seven major markets following the FDA's decision and, as a result, Rituxan looks set to dominate in this indication.
Published By Datamonitor
|
02 Feb 2011 |
|
CommentWire
|
New data indicate that the addition of aflibercept to docetaxel as a second-line treatment for patients with non-small cell lung cancer failed to improve overall survival in a Phase III trial. On the basis of these results and given the competitive landscape of the non-small cell lung cancer market, it is unlikely that Sanofi-Aventis and Regeneron will pursue an approval for this indication.
Published By Datamonitor
|
15 Mar 2011 |
|
CommentWire
|
Encouraged by a partnership that has to date been successful, Millennium has invested further into Seattle Genetics' antibody-drug conjugate technology. As the wait for the first commercially successful antibody-drug conjugate therapeutic continues, pharmaceutical players are actively populating their pipelines with this innovative monoclonal antibody class.
Published By Datamonitor
|
17 Mar 2011 |
|
CommentWire
|
As Cephalon faces declining sales across its key central nervous system franchise due to generic sales erosion, the company continues to pursue a strategy of acquisition in order to further diversify its product portfolio. The Gemin X agreement could provide potential long-term growth for Cephalon's expanding oncology interest.
Published By Datamonitor
|
23 Mar 2011 |
|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.